NCT01344083View on ClinicalTrials.gov

Comparison of the Efficacy and Tolerability of T1210 and Olopatadine Hydrochloride 0.1% in the Treatment of Seasonal Allergic Conjunctivitis

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Seasonal Allergic Conjunctivitis
Interventions
DRUG

T1210

2 drops T1210 once a day

DRUG

Olopatadine hydrochloride

2 drops once a day Olopatadine

Trial Locations (1)

63000

Pierre Huguet, Clermont-Ferrand

Sponsors

Lead Sponsor

Laboratoires Thea
All Listed Sponsors
lead

Laboratoires Thea

INDUSTRY